简
/
繁
/
EN
About Us
R&D
Products
News
Careers
Investors
Contact us
Investors
（02186.HK）
HK$
➚
%
Volume(M)
0thousand
Turnover(HK $)
0thousand
Data as of：
Announcement & Circular
Corporate Governance
Financial Results
IR Activities
Contact IR
Year
2022
2023
2024
2025
2026
24
2024-01
Voluntary Announcement both BA1105 and BA1301 being Granted Orphan Drug Designations for Treatment of Gastric Cancer by FDA
17
2024-01
Voluntary Announcement the Company has Obtained GMP Certification for Boyuno from the Brazilian Agencia Nacional de Vigilancia Sanitaria
04
2024-01
Voluntary Announcement Enrollment of Subjects Completed for International Multi-Center Comparative Clinical (Phase 3) Study of Denosumab Injection
03
2024-01
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2023
29
2023-12
Voluntary Announcement Voluntary Lock-up Undertakings by Certain Shareholders
27
2023-12
Both BA1105 and BA1301 Being Granted Orphan Drug Designations for Treatment of Pancreatic Cancer by the FDA
22
2023-12
Finance Lease Agreement
12
2023-12
Resignation of Non-Executive Director
12
2023-12
List of Directors and their Roles and Functions
01
2023-12
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2023
8
9
10
11
12
Follow me
鲁公网安备37069102000284